Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. (Q53594098)

16 May 2018

title

Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. (English)

1 reference

16 May 2018

0 references

1 reference

Eisenberg JD

1

1 reference

16 May 2018

Aitken ML

2

1 reference

16 May 2018

Dorkin HL

3

1 reference

16 May 2018

Harwood IR

4

1 reference

16 May 2018

Ramsey BW

5

1 reference

16 May 2018

Schidlow DV

6

1 reference

16 May 2018

Wilmott RW

7

1 reference

16 May 2018

Wohl ME

8

1 reference

16 May 2018

Fuchs HJ

9

1 reference

16 May 2018

Christiansen DH

10

1 reference

16 May 2018

Smith AL

11

1 reference

16 May 2018

language of work or name

English

0 references

publication date

1 July 1997

1 reference

16 May 2018

The Journal of Pediatrics

published in

1 reference

16 May 2018

volume

131

1 reference

16 May 2018

issue

1 Pt 1

1 reference

16 May 2018

page(s)

118-124

1 reference

16 May 2018

Liquefaction of viscous purulent exudates by deoxyribonuclease

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

PURIFICATION AND PROPERTIES OF DESOXYRIBONUCLEASE ISOLATED FROM BEEF PANCREAS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

The relation between genotype and phenotype in cystic fibrosis--analysis of the most common mutation (delta F508).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

A new prognostic score and clinical evaluation system for cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

Single breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique. Statement of the American Thoracic Society

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

Standardization of lung function testing in children. Proceedings and Recommendations of the GAP Conference Committee, Cystic Fibrosis Foundation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

Standardization of spirometry--1987 update. Statement of the American Thoracic Society

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

Comparison of scales used to quantitate the sense of effort to breathe in patients with chronic obstructive pulmonary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

Immunogenicity of recombinant DNA human insulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

Deoxyribonuclease in the treatment of purulent bronchitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

Aerosolized pancreatic dornase and antibiotics in pulmonary infections: use in patients with postoperative and nonoperative infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

Dornase Aerosol Effect on Sputum Viscosity in Cases Of Cystic Fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

Allergic reactions of the lungs to enzymes of Bacillus subtilis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

Immediate Hypersensitivity to Hog Trypsin Resulting from Industrial Exposure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

Respiratory hazards from proteolytic enzymes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

10.1016/S0022-3476(97)70134-3

7 January 2021

Identifiers

DOI

1 reference

16 May 2018

PubMed ID

9255202

1 reference

16 May 2018